


Impact of the Inflation Reduction Act on Cancer Care: A Virtual Workshop Series Part 1

Convened by the National Cancer Policy Forum in collaboration with the
Forum on Drug Discovery, Development, and Translation



NATIONAL
ACADEMIES *Sciences
Engineering
Medicine*

September 8, 12:00 – 1:30 PM ET

Impact of the Inflation Reduction Act on Cancer Care:
A Virtual Workshop Series (Part 1)

VIRTUAL WORKSHOP

Link to view the live webcast:


[Impact of the Inflation Reduction Act on Cancer Care: A Virtual Workshop Series
\(Part 1\)](#) | National Academies

Impact of the Inflation Reduction Act on Cancer Care: A Virtual Workshop Series Part 1

September 8, 2026

National Cancer Policy Forum in collaboration with the
Forum on Drug Discovery, Development, and Translation

[Workshop Website](#)



VIRTUAL WORKSHOP AGENDA

PART 1: TUESDAY, SEPTEMBER 8 12:00 pm– 1:30 pm (Eastern Time Zone)	
12:00 pm	Welcome and Opening Remarks (10 minutes) Cleo Ryals, Planning Committee Co-chair
12:10	Keynote Presentation: The Inflation Reduction Act and Prescription Drugs: An Overview (~20 minutes) <i>Moderator:</i> Cleo Ryals, Flatiron Health Michelle Mello, Stanford University School of Medicine
12:30	Panel: Inflation Reduction Act: Changes in Access to Medicines (~55 minutes) <i>Co-moderators:</i> Nancy Keating, Harvard Medical School; Brigham and Women's Hospital Kirsten Axelsen, DLA Piper Each panelist to make up to 7-minute opening remarks A Patient/Patient Advocate Perspective: Navigating Treatment and Care Over Time - Gwen Darien, Patient Advocate Foundation Self-Administered Medications and Part D Perspective - Benjamin Rome, Brigham and Women's Hospital; Program On Regulation, Therapeutics, And Law Physician-Administered Medications and Community Oncology Perspective - Laura Johnetta Blakely, The Community Oncology Alliance Panel Discussion and Audience Q&A (~35 minutes)
1:25	Closing Remarks (5 minutes) Stacie Dusetzina, Planning Committee Co-chair
1:30	Adjourn

Meeting Information

Impact of the Inflation Reduction Act on Cancer Care:
A Virtual Workshop Series (Part 1)

September 8, 2026, 12:00 PM - 1:30 PM (EDT)

Virtual:

Link to live webcast

[Impact of the Inflation Reduction Act on Cancer Care: A Virtual Workshop Series \(Part 1\)](#)

Guidance for Virtual Attendees:

- We welcome your involvement in the workshop. Please join the public chat using [SLIDO](#) (located below the livestream) to ask questions and submit comments.
- Supplemental materials are available for download on our [Event Page](#).
- The workshop is being webcast and recorded. Video recordings and copies of slide presentations will be posted on the webpage within 1-2 weeks.

Current Sponsors of the National Cancer Policy Forum

American Association for Cancer Research

American Cancer Society

American College of Radiology

American Society of Clinical Oncology

Association of American Cancer Institutes

AVEO Oncology

Cancer Center at Illinois

Flatiron Health

Lilly

Merck

National Comprehensive Cancer Network

Novartis Oncology

Oncology Nursing Society

Partners In Health

Patient Advocate Foundation

Pfizer Inc

Vibrent Health

We are grateful for the support of our sponsors, which is crucial to the work of the Forum.

Impact of the Inflation Reduction Act on Cancer Care: A Virtual Workshop Series

Part 1

September 8, 2026

Planning Committee Roster

Stacie Dusetzina, PhD (Co-chair)

Professor, Health Policy
Ingram Professor of Cancer Research
Vanderbilt University School of Medicine

Cleo Ryals, PhD (Co-chair)

Senior Director, Community Oncology
Research Partnerships
Flatiron Health

Kirsten Judith Axelsen Carmel, MS

Senior Policy Advisor, DLA Piper
Senior Policy Advisor, Charles River Associates
Policy Advisor, Real Chemistry
Independent Consultant
Grasshopper Industries LLC

Roy S. Herbst, MD, PhD

Director, Dartmouth Cancer Center
Associate Dean of Cancer Programs
Professor of Microbiology and Immunology and
of Medicine
Preston T. and Virginia R. Kelsey Distinguished Chair
in Cancer
Geisel School of Medicine at Dartmouth

Nancy L. Keating, MD, MPH

Professor of Health Care Policy & Medicine
Harvard Medical School
Program Leader, Cancer Care Delivery
Research Program
Harvard Cancer Consort

Megan Tweed, MPP

Associate Director
Oncology Corporate Affairs, External Engagement
Lilly

Impact of the Inflation Reduction Act on Cancer Care: A Virtual Workshop Series

Part 1

September 8, 2026

Speaker Roster

Laura Johnetta Blakely, MD, MS, MMHC

Chief Medical Officer, Community Oncology Alliance
Physician Partner, Hematology/Oncology
Tennessee Oncology

Gwen Darien, BA

Chief Patient Engagement Officer
Patient Advocate Foundation

Michelle Mello, JD, PhD

Professor of Law, Stanford Law School
Professor of Health Policy, Department of
Health Policy
Stanford University School of Medicine

Benjamin N. Rome, MD, MPH

Assistant Professor of Medicine, Harvard Medical School
Program On Regulation, Therapeutics and Law
Brigham and Women's Hospital

Impact of the Inflation Reduction Act on Cancer Care: A Virtual Workshop Series

Part 1

September 8, 2026

Planning Committee Biosketches



Stacie Dusetzina, PhD (Co-chair)
Vanderbilt University School of Medicine

Dr. Stacie Dusetzina is a professor of Health Policy and an Ingram professor of cancer research at Vanderbilt University School of Medicine, Department of Health Policy. She is a health services researcher focusing on the intersection between health policy, epidemiology, and economics related to prescription drugs.

Dr. Dusetzina has been recognized for her work at a national level, advising Congressional committees and multiple government agencies on prescription drug legislation. She is currently serving as a member of the Medicare Payment Advisory Commission and was recently elected to the National Academy of Medicine for her work related to prescription drug pricing and

access.



Cleo Ryals, PhD (Co-chair)
Flatiron Health

Dr. Cleo A. Ryals is the Head of Health Equity Research at Flatiron Health, where she is tasked with developing and executing Flatiron's company-wide health equity strategy with the goal of advancing cancer health equity through real-world evidence generation. Dr. Ryals is a health services researcher by training with expertise in cancer health equity, real-world data and evidence generation, health equity research methodology and data analytics, clinical trial diversity, and community engagement. She is a nationally recognized and highly sought after health equity researcher and leader with several publications on topics related to health equity and oncology care.

Prior to joining Flatiron Health, Dr. Ryals was a tenured Associate Professor of Health Policy and Management at the UNC Chapel Gillings School of Global Public Health, where she built substantial health equity research and training programs and was the Founding Director of the Centering Racial Equity in Data Science (CREDS) Initiative at the UNC Lineberger Comprehensive Cancer Center. Dr. Ryals has also held positions within multiple federal offices/agencies, including the former United States Senate Office of Barack Obama, the Office of the National Coordinator for Health Information Technology, and the Government Accountability Office. In 2019, Dr. Ryals was recognized as a '40 Under 40' Leader in Minority Health by the National Minority Quality Forum and Congressional Black Caucus. Dr. Ryals holds a PhD in Health Policy from Harvard University.



Kirsten Judith Axelsen Carmel, MS
DLA Piper

Ms. Kirsten Judith Axelsen Carmel works with leaders in life sciences to navigate policy, competition, reimbursement, and public perception for successful product launch, growth, and profitability. She has experience developing and executing strategy at all stages of the biopharmaceutical lifecycle in all major markets.

Ms. Axelsen Carmel brings more than 25 years of experience in life sciences and was previously on the leadership team of Pfizer's global innovative pharmaceutical business. She is a Senior Policy Advisor to DLA Piper and Charles River Associates and an Aspen Institute Health Fellow.



Roy S. Herbst, MD, PhD
Dartmouth Cancer Center

Dr. Roy Herbst is an internationally recognized leader in the development of targeted and immune-based therapies for lung cancer. His pioneering research on EGFR-targeted treatments and immunotherapy transformed precision oncology, leading to the approval of multiple groundbreaking therapies and establishing new standards of care. He has advanced personalized medicine through innovative clinical trial designs, including the BATTLE and Lung-MAP programs, and his work on biomarkers of treatment response has improved outcomes for patients worldwide. After earning degrees from Yale, Cornell, Rockefeller University, and Harvard, he held leadership positions at The University of Texas MD Anderson Cancer Center and Yale Cancer Center before joining Dartmouth. He has authored more than 500 scientific publications, secured major NIH and industry-supported research grants, and remains one of the world's most influential investigators in thoracic oncology.

In addition to his research accomplishments, Dr. Herbst is a distinguished clinician, educator, and national leader in cancer policy. He has served in leadership roles with organizations including ASCO, AACR, IASLC, and the National Academy of Medicine, while advocating for tobacco control, innovative clinical trials, and public-private partnerships in cancer research. His many honors include the IASLC Paul A. Bunn, Jr. Scientific Award, the AACR Distinguished Public Service Award, the Giants of Cancer Care® Award, election to the Association of American Physicians and the Connecticut Academy of Science and Engineering. Through his mentorship, educational leadership, and commitment to compassionate patient care, Dr. Herbst has helped shape the next generation of physician-scientists while leaving a lasting impact on cancer research and treatment.



Nancy L. Keating, MD, MPH


Harvard Medical School; Brigham and Women's Hospital

Dr. Nancy L. Keating is Professor of Health Care Policy and Medicine at Harvard Medical School and a primary care physician at Brigham and Women's Hospital. She is Program Leader of the Harvard Cancer Consortium's Cancer Care Delivery Research Program.

Dr. Keating's research studies care delivery for individuals with cancer, including access to care, quality of care, and how we pay for and deliver care. In ongoing work, she is studying the impact of financial integration of oncology practices into systems and hospitals and its impact on care delivery. Other recent and ongoing work assesses affordability of prescription drugs for patients with cancer, health insurers' use of utilization management tools, and patients' experiences with administrative burden. She previously served as Clinical Lead of the Evaluation Team for the

Center for Medicare and Medicaid Service's Oncology Care Model, an alternate payment and delivery model for oncology practices administering chemotherapy. The evaluation assessed spending, quality of care, health care utilization, and patients' experiences for patients receiving chemotherapy in approximately 200 participating practices compared with non-participating practices. She has also studied patient, physician, and health system factors contributing to the variations in the intensity of end-of-life care for individuals with advanced cancer and she has studied interventions to improve patients' understanding of the goals of chemotherapy and to improve patients' discussions with their clinicians about their preferences and goals of care.

Dr. Keating received her MD degree from the University of Chicago Pritzker School of Medicine, and her MPH degree from the Harvard TH Chan School of Public Health. In 2022, she was awarded the John M. Eisenberg Award for Career Achievement in Research by the Society of General Internal Medicine. She currently serves as a member of the National Cancer Policy Forum. She is an elected member of the American Society for Clinical Investigation and the Association of American Physicians. Dr. Keating has been continuously funded by the National Institutes of Health as principal investigator for more than twenty years. She co-leads a T32 training grant, Training in Oncology Population Sciences. She is a member of the editorial board of *Annals of Internal Medicine* and the *Journal of Clinical Oncology*, previously served as an Associate Editor at the *Journal of the National Cancer Institute*, and she is member of the National Comprehensive Cancer Center Senior Oncology Guideline Panel.



Megan Tweed, MPP

Lilly

Ms. Megan Tweed is the Associate Director - Oncology Corporate Affairs: External Engagement at Lilly. Previously, she served as Public Health Advisor at the FDA's Center for Drug Evaluation and Research (CDER) and held significant government affairs roles at the Association for Clinical Oncology (ASCO) and the American Gastroenterological Association (AGA).

Ms. Tweed's expertise lies in public affairs, healthcare policy, legislative analysis, and strategic communications. She has a proven track record in coalition building, stakeholder engagement, and advising senior leadership on federal healthcare legislation and reimbursement policy.

Ms. Tweed holds a Master of Public Policy in Global Health from American University and a Bachelor of Arts in Communications and International Studies from Niagara University.

Impact of the Inflation Reduction Act on Cancer Care: A Virtual Workshop Series

Part 1

September 8, 2026

Speaker Biosketches



Laura Johnetta Blakely, MD, MS, MMHC
Community Oncology Alliance; Tennessee Oncology

Dr. Laura Johnetta Blakely is Chief Medical Officer of the Community Oncology Alliance (COA) and a Physician Partner in Hematology/Oncology at Tennessee Oncology, where she previously served as Executive Vice President of Quality and Clinic Operations and Executive Director of Health Economics and Outcomes Research. Board-certified in internal medicine and medical oncology, she has practiced community oncology in Tennessee for more than two decades, treating patients with breast, lung, and colorectal cancers and sarcoma.

Dr. Blakely's work spans clinical care, health economics, and policy. She serves on COA's Government Affairs Committee and OneOncology's National Physician Executive Board, and has advised on drug pricing, reimbursement, and payment reform affecting community oncology practices nationwide. She holds an MD from the University of Tennessee, a Master of Clinical Research from MD Anderson Cancer Center/University of Texas, and a Master of Management in Health Care from Vanderbilt University's Owen School of Business.

Dr. Blakely lives in Nashville, Tennessee. She is married and has two adult children.



Gwen Darien, BA
Patient Advocate Foundation

Ms. Gwen Darien is a long-time patient advocate who has played leadership roles in some of the country's preeminent nonprofit organizations. As Chief Patient Engagement Officer for patient advocacy, engagement and education, Ms. Darien leads programs that link Patient Advocate Foundation's direct patient service programs to PAF patient engagement and system change initiatives, with the goal of improving access to equitable, affordable, quality health care.

As a four-time cancer survivor herself, Ms. Darien came into cancer advocacy expressly to change the experiences and outcomes for the patients who came after her, to change the public dialogue about cancer and other life-threatening illnesses. The foundational value for her advocacy work is achieving equitable health outcomes for everyone. She began her advocacy work as editor and publisher of Mamm, a magazine for women with breast or reproductive cancer, she published features on previously taboo subjects, such as dating after a mastectomy, along with the more expected academic features on news and policy analysis.

With these goals in mind, in 2005 Ms. Darien started the first stand-alone advocacy entity in a professional cancer research organization at the American Association for Cancer Research. At AACR, she launched CR magazine – a magazine for people with cancer and those who care for them. Later, she served as the executive vice president of programs and services at the Cancer Support Community. In each role, Darien championed placing patients at the center of health system change, whether it is for research, public policy or direct services.

Ms. Darien serves on a wide range of program committees and workshop faculties. She is a member of the National Cancer Policy Forum of the National Academies of Science, Engineering and Medicine for which she is co-chairing the forthcoming workshop, National Cancer Policy Summit 2026: Progress in Policy and Science and the Future of Cancer Research and Care. Gwen is a member of the NAM Leadership Consortium's Clinician's Forum on AI. She co-chaired the Individual and Community Health Goals working group of the National Academy of Medicine's Commission on

Investment Imperatives for a Healthy Nation. Ms. Darien is the past Chair of PCORI's Patient Engagement Advisory Panel and was founding Chair of Community Engagement in Genomics Working Group of the National Human Genome Research. Gwen also writes about her experiences as an advocate and cancer survivor. Her piece, Transformation: My Experience as a Patient and an Advocate in Three Chapters appeared in the National Academy of Medicine Perspectives.

Ms. Darien is a graduate of Sarah Lawrence College, where she also served as an adviser for their Health Advocacy program.



Michelle Mello, JD, PhD
Stanford University School of Medicine

Dr. Michelle Mello is Professor of Law at Stanford Law School and Professor of Health Policy in the Department of Health Policy at Stanford University School of Medicine. She conducts empirical research into issues at the intersection of law, ethics, and health policy. She is the author of nearly 300 articles on medical liability, public health law, the public health response to COVID-19, artificial intelligence, pharmaceuticals and vaccines, data ethics and privacy, research ethics and governance, and other topics. She is co-director of the Healthcare Ethical Assessment Lab for Artificial Intelligence (HEAL-AI) at Stanford, which conducts ethical assessments of AI tools proposed for deployment at Stanford Health Care facilities.

The recipient of a number of awards for her research, Dr. Mello was elected to the National Academy of Medicine at the age of 40. From 2000 to 2014, she was a professor at the Harvard School of Public Health, where she directed the School's Program in Law and Public Health.

Dr. Mello teaches in the areas of torts, public health law, and health policy. She holds a J.D. from the Yale Law School, a Ph.D. in Health Policy and Administration from the University of North Carolina at Chapel Hill, an M.Phil. from Oxford University, where she was a Marshall Scholar, and a B.A. from Stanford University.



Benjamin N. Rome, MD, MPH
Harvard Medical School; Brigham and Women's Hospital

Dr. Benjamin Rome is Assistant Professor at Harvard Medical School and a PORTAL faculty member. A general internist and health policy researcher, his work examines how federal and state policies influence the regulation, use, and cost of prescription drugs, and the resulting effects on patient access, affordability, and clinical outcomes. Dr. Rome's work has been published in the New England Journal of Medicine, JAMA, Health Affairs, and BMJ. His research has been featured in a Congressional report on rising prescription drug prices, and he has testified about the regulation and cost of medications before the US House of Representatives. In 2022, he was selected as an Emerging Leaders in Health and Medicine Scholar by the National Academy of Medicine.

Dr. Rome received his undergraduate degree in community health from Brown University, his medical degree from Harvard Medical School, and his Master of Public Health from the Harvard T.H. Chan School of Public Health. He trained in internal medicine at Brigham and Women's Hospital and is a practicing primary care physician at Brigham and Women's Hospital.

National Cancer Policy Forum Staff Biosketches



Francis Kwadwo Amankwah, MPH

Director
National Cancer Policy Forum
Program on Health Care and Public Health
Center for Health, People, & Places

Mr. Francis Amankwah serves as Director of the National Cancer Policy Forum. In 2024, he co-directed the Forum with Dr. Sharyl Nass. For more than 11 years, his work has focused on health disparities, public health, cancer care and research, primary care, drug pricing, and health services research. He has managed numerous consensus study committees, most recently producing the 2024 consensus report *Ending Unequal Treatment: Strategies to Achieve Equitable Health Care and Optimal Health*. He has also contributed to several cancer-related consensus studies, including *Rethinking Race and Ethnicity in Biomedical Research* (2025), *Guiding Cancer Control: A Path to Transformation* (2019), and *Making Medicines Affordable: A National Imperative* (2017). He has also served as responsible staff officer for numerous workshops and convening activities and as rapporteur for several workshop proceedings and proceedings-in-brief. He is a recipient of the Health and Medicine Division Elena Nightingale, Veteran, Mount Everest, and Fineberg staff achievement awards. He is currently pursuing a Ph.D. in Health Services Research at George Mason University. He earned his M.P.H. and a graduate certificate in Global Planning and International Development from Virginia Tech. Raised in Ghana, West Africa, he received his B.S. in Agricultural Science from Kwame Nkrumah University of Science and Technology.



Torrie Brown, BA

Program Coordinator
Program on Health Care and Public Health
Center for Health, People, & Places

Ms. Torrie Brown is the Program Coordinator for the Health Care and Public Health program at the National Academies of Sciences, Engineering, and Medicine. She served as both a program coordinator and senior program assistant with the National Academies' former Board on Health Care Services, where she has provided support to projects spanning topics across the health care spectrum. She has a particular interest in health care and public health initiatives at the intersections of disability and rehabilitation. Ms. Brown earned her Bachelor of Arts in anthropology from the University of Maryland, College Park, and has served in various roles within organizations such as the U.S. House of Representatives, Drug Policy Alliance, and Public Citizen.



Makeda Haughton, BA

Senior Program Assistant
Program on Health Care and Public Health
Center for Health, People, & Places

Ms. Makeda Haughton serves as a Senior Program Assistant at the National Academies of Sciences, Engineering, and Medicine, where she supports senior leadership and advances high-impact initiatives within the National Cancer Policy Forum. She plays a key role in planning and executing strategic convenings and managing core operational functions. Ms. Haughton holds a Bachelor of Arts in Communication from the University of Central Florida.

**Sharyl J. Nass, PhD**

Senior Program Director
Program on Health Care and Public Health
Center for Health, People, & Places

Dr. Sharyl Nass serves as Senior Program Director for Health Care and Public Health at the National Academies of Sciences, Engineering, and Medicine. The National Academies provide independent, objective analysis and advice to the nation to solve complex problems and inform public policy decisions related to science, technology, and medicine. The Health Care and Public Health program addresses the delivery of primary and specialty health care across the life course, including care quality and patient safety, workforce, training, and financing, as well as public health services, including prevention, surveillance, epidemiology, and population health

improvement. For more than 25 years, Dr. Nass has worked on a broad range of health and science policy topics that include cancer research and care, the quality and safety of health care and clinical trials, developing technologies for precision medicine, and strategies to support clinician and patient well-being. She has a Ph.D. from Georgetown University and undertook postdoctoral training at the Johns Hopkins University School of Medicine, as well as a research fellowship at the Max Planck Institute in Germany. She also holds a B.S. and an M.S. from the University of Wisconsin–Madison. She has been the recipient of the Cecil Medal for Excellence in Health Policy Research, a Distinguished Service Award from the National Academies, the Institute of Medicine staff team achievement award (as team leader), and the Health and Medicine Division Mentor Award.

Upcoming Workshop

Impact of the Inflation Reduction Act on Cancer Care: A Virtual Workshop Series (Part 2)

October 6, 2026

VIRTUAL

National Cancer Policy Forum

[Workshop Website](#)

Workshop Statement of Task

A planning group of the National Academies of Sciences, Engineering, and Medicine will organize and conduct a series of public virtual workshops to explore the health care provisions of the 2022 Inflation Reduction Act and discuss the implications for access to high-quality care for chronic diseases and innovation in drug development in the United States, with particular attention to cancer care. The virtual workshops will feature invited presentations by experts in drug development, health policy, clinical care, health economics, reimbursement, including representatives from industry, academia, government agencies, and people with lived experience.

The second virtual workshop will explore early evidence and modeling related to patient access, affordability, and coverage decisions for cancer care. Topics may include:

- Potential impact of cost-sharing caps and pricing reforms on Medicare beneficiaries with cancer.
- Implications for formulary design and utilization management, and coverage decisions.
- Potential impact on health disparities across the care continuum.
- Unique considerations in oncology, such as the use of high-cost specialty drugs.

The planning committee will develop the agenda for the virtual workshop sessions, select and invite speakers and discussants, and moderate the discussions. A proceedings-in-brief of the presentations and discussions at the virtual workshop series will be prepared by a designated rapporteur in accordance with institutional guidelines.

Upcoming Workshop

Impact of the Inflation Reduction Act on Cancer Care: A Virtual Workshop Series (Part 3)

December 15, 2026

VIRTUAL

National Cancer Policy Forum

[Workshop Website](#)

Workshop Statement of Task

A planning group of the National Academies of Sciences, Engineering, and Medicine will organize and conduct a series of public virtual workshops to explore the health care provisions of the 2022 Inflation Reduction Act and discuss the implications for access to high-quality care for chronic diseases and innovation in drug development in the United States, with particular attention to cancer care. The virtual workshops will feature invited presentations by experts in drug development, health policy, clinical care, health economics, reimbursement, including representatives from industry, academia, government agencies, and people with lived experience.

The third virtual workshop will examine potential implications of the IRA for innovation in research and development across chronic diseases, with a focus on cancer. Topics may include:

- Early analyses or signals related to research investment, clinical trials, and drug development pipelines.
- Differences in implications across therapeutic areas.
- Potential impacts on small and emerging companies.
- Policy or system-level approaches to support continued innovation in light of IRA provisions with sustained incentives for research, development, and post-approval evidence generation.

The planning committee will develop the agenda for the virtual workshop sessions, select and invite speakers and discussants, and moderate the discussions. A proceedings-in-brief of the presentations and discussions at the virtual workshop series will be prepared by a designated rapporteur in accordance with institutional guidelines.

Upcoming Workshop

National Cancer Policy Summit 2026: Progress in Policy and Science and the Future of Cancer Research and Care

November 9 - 10, 2026

National Cancer Policy Forum

Keck Center Room 100
500 Fifth Street, NW
Washington, DC 20001

[Workshop Website](#)

Workshop Statement of Task

A National Academies of Sciences, Engineering, and Medicine planning committee will organize a public summit to reflect on the major policy and science developments in cancer research and cancer care over the past 20 years since the launch of the National Cancer Policy Forum, and identify and discuss the key policy challenges and opportunities to further advance research and patient care for the future. The summit will feature invited presentations and panel discussions on topics that may include:

- Examples of major insights and developments in science, clinical care, and policy for cancer that have occurred in the past 20 years and their impact on patient outcomes.
- Lessons from the challenges and opportunities in the past 20 years that could be applied to guide next steps.
- Potential strategies to foster future efforts to advance cancer research and care.

The planning committee will develop the agenda for the summit sessions, select and invite speakers and discussants, and moderate or identify moderators for the discussions. A proceedings-in-brief of the presentations and discussions at the summit will be prepared by a designated rapporteur in accordance with institutional guidelines.

Preventing Discrimination, Harassment, and Bullying: Policy for Participants in National Academies Activities

Purpose

To prohibit discrimination, harassment, and bullying for all participants in National Academies activities.

Applicability

All participants in all settings and locations in which the National Academies work and activities are conducted.

Preventing Discrimination, Harassment, and Bullying: Policy for Participants in National Academies Activities

The National Academies of Sciences, Engineering, and Medicine (National Academies) are committed to the principles of integrity, civility, and respect in all of our activities. We look to you to be a partner in this commitment by helping us to maintain a professional and cordial environment. **All forms of discrimination, harassment, and bullying are prohibited in any National Academies activity.** This policy applies to all participants in all settings and locations in which the National Academies work and activities are conducted, including committee meetings, workshops, conferences, and other work and social functions where employees, volunteers, sponsors, vendors, or guests are present.

Definitions

Discrimination is prejudicial treatment of individuals or groups of people based on their race, color, national origin, sex, age, religion, disability, veteran status, or any other characteristic protected by applicable laws.

Sexual harassment is unwelcome sexual advances, requests for sexual favors, and other verbal or physical conduct of a sexual nature that creates an intimidating, hostile, or offensive environment.

Other types of harassment include any verbal or physical conduct directed at individuals or groups of people because of their race, ethnicity, color, national origin, sex, sexual orientation, gender identity, age, religion, disability, veteran status, or any other characteristic protected by applicable laws, that creates an intimidating, hostile, or offensive environment.

Bullying is unwelcome, aggressive behavior involving the use of influence, threat, intimidation, or coercion to dominate others in the professional environment.

Reporting and Resolution

Any violation of this policy should be reported. If you experience or witness discrimination, harassment, or bullying, you are encouraged to make your unease or disapproval known to the individual at the time the incident occurs, if you are comfortable doing so. You are also urged to report any incident by:

- Filing a complaint through the National Academies Complaint Intake Form (<https://nas.hracity.net/webform/index/a5ed0226-f5e5-4da4-be0d-1daf8976f594>), and/or
- Filing a complaint with the Office of Human Resources at 202-334-3400 or hrservicecenter@nas.edu, or
- Reporting the incident to an employee involved in the activity in which the member or volunteer is participating, who will then file a complaint with the Office of Human Resources.

Complaints should be filed as soon as possible after an incident. To ensure the prompt and thorough investigation of the complaint, the complainant should provide as much information as is possible, such as names, dates, locations, and steps taken. The Office of Human Resources will investigate the alleged violation in consultation with the Office of the General Counsel.

If an investigation results in a finding that an individual has committed a violation, the National Academies will take the actions necessary to protect those involved in its activities from any future discrimination, harassment, or bullying, including in appropriate circumstances **the removal of an individual from current National Academies activities and a ban on participation in future activities.**

Confidentiality

Information contained in a complaint is kept confidential, and information is revealed only on a need-to-know basis. The National Academies will not retaliate or tolerate retaliation against anyone who makes a good faith report of discrimination, harassment, or bullying.

Responsible Party

The NRC Executive Officer is responsible for oversight of and substantive changes to the policy.